Skip to main content
Premium Trial:

Request an Annual Quote

Raymond James Upgrades Quidel

NEW YORK (GenomeWeb News) – Raymond James Equity Research today upgraded Quidel to Outperform and established a price target of $22, noting expected new products throughout the year that should expand the company's revenue base.

In a research note analyst Nicholas Jansen upgraded the San Diego-based firm's rating from Market Perform and said that 2013 "will serve as an inflection point for Quidel as the company begins to accrue the benefits from its spate of new product introductions that should ultimately help diversify the revenue base of the company, which today, is still heavily dependent on influenza."

He said that in 2013 Quidel is anticipated to launch 10 new products. During the past three years, it has invested heavily in R&D to broaden its revenue base beyond influenza, which makes up between 20 and 30 percent of total revenues. This year, he said, the fruits of the diversification effort should be realized.

In addition to the launch of the Sophia immunoassay system in 2012, Jansen noted the recent approval from the US Food and Drug Administration of Quidel's C. difficile test on its AmpliVue handheld molecular system, which provides the firm entry into the hospital-acquired infection space. He added that other open-box assays could receive approval this year, "boding well for 2014 growth."

The flu season is also shaping up to be a growth driver in the near term, and during the past five weeks flu activity has spiked. Quidel also faces an easy year-ago comparison when the flu season was weak.

"While the stock has already started to react to the news, we believe there is more upside should the season remain strong in 1Q13," Jansen said.

Quidel shares were up 5 percent at $19.55 on the Nasdaq in Wednesday morning trade.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.